Skip to main content
. 2019 Nov 8;22(4):515–549. doi: 10.1093/europace/euz246

Table 3.

Pooled effect estimates for potential risk factors predisposing to cardiac implantable electronic device infection

Prospective + retrospective studies
Prospective studies only
Factor Studies (n) Total (n) Pooled estimate P-value Studies (n) Total (n) Pooled estimate P-value
Patient-related factors
 ESRDa 8 3045 8.73 [3.42, 22.31] 0.00001 NA
 History of device infection 4 463 7.84 [1.94, 31.60] 0.004 NA
 Fever prior to implantation 3 6652 4.27 [1.13, 16.12] 0.03 2 6580 5.34 [1.002, 28.43] 0.05
 Corticosteroid use 10 3432 3.44 [1.62, 7.32] 0.001 3 1349 2.10 [0.47, 9.32] 0.33
 Renal insufficiencyb 5 2033 3.02 [1.38, 6.64] 0.006 NA
 COPD 6 2810 2.95 [1.78, 4.90] 0.00003 2 2393 2.30 [0.97, 5.48] 0.06
 NYHA class ≥ 2 3 2447 2.47 [1.24, 4.91] 0.01 2 2393 2.77 [1.26, 6.05] 0.01
 Skin disorders 4 6810 2.46 [1.04, 5.80] 0.04 2 6519 2.60 [0.88, 7.70] 0.08
 Malignancy 6 1555 2.23 [1.26, 3.95] 0.006 NA
 Diabetes mellitus 18 11839 2.08 [1.62, 2.67] <0.000001 7 9815 1.88 [1.19, 2.98] 0.007
 Heparin bridging 2 6373 1.87 [1.03, 3.41] 0.04 NA
 CHF 6 1277 1.65 [1.14, 2.39] 0.008 NA
 Oral anticoagulants 9 8527 1.59 [1.01, 2.48] 0.04 3 7271 1.18 [0.44, 3.11] 0.75
Procedure-related factors
 Procedure duration 9 4850 9.89 [0.52, 19.25] 0.04 6 4508 13.04 [-0.64, 26.73] 0.06
 Haematoma 12 14228 8.46 [4.01, 17.86] <0.000001 6 9715 9.33 [2.84, 30.69] 0.0002
 Lead repositioning 5 1755 6.37 [2.93, 13.82] 0.000003 4 1659 7.03 [2.49, 19.85] 0.0002
 Inexperienced operatorc 2 1715 2.85 [1.23, 6.58] 0.01 2 1715 2.85 [1.23, 6.58] 0.01
 Temporary pacing 10 10683 2.31 [1.36, 3.92] 0.002 4 8683 3.29 [1.87, 5.80] 0.00004
 Device replacement/revision/upgrade 26 21214 1.98 [1.46, 2.70] 0.00001 8 8793 0.95 [0.49, 1.87] 0.89
 Generator change 20 12134 1.74 [1.22, 2.49] 0.002 6 2139 0.91 [0.37, 2.22] 0.83
 Antibiotic prophylaxis 16 14166 0.32 [0.18, 0.55]d 0.00005 11 10864 0.29 [0.13, 0.63] 0.002
Device-related factors
 Epicardial leads 3 623 8.09 [3.46, 18.92] 0.000001 NA
 Abdominal pocket 7 4017 4.01 [2.48, 6.49] <0.000001 2 2268 5.03 [1.96, 12.91] 0.0008
 ≥2 leads 6 1146 2.02 [1.11, 3.69] 0.02 NA
 Dual-chamber device 14 45224 1.45 [1.02, 2.05] 0.04 7 12102 1.28 [0.73, 2.25] 0.38

Risk parameters which were statistically significant for retrospective and prospective data are shown. Analyses restricted to prospective data only for the same parameters (if available) are also shown. Adapted from Polyzos et al.21

CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; ESRD, end-stage renal disease; NA, not available; NYHA, New York Heart Association.

a

GFR ≤15  mL/min or haemodialysis or peritoneal dialysis.

b

Glomerular filtration rate (GFR) <60 mL/min or creatinine clearance (CrCL) <60  mL/min.

c

<100 previous procedures.

d

The pooled effect estimate from randomized studies was 0.26 [0.13, 0.52].